Stereotactic ablative radiotherapy for comprehensive treatment of oligometastatic tumors (SABR-COMET): Study protocol for a randomized phase II trial

Stereotactic ablative radiotherapy for comprehensive treatment of oligometastatic tumors (SABR-COMET): Study protocol for a randomized phase II trial

<p>Abstract</p> <p>Background</p> <p>Stereotactic ablative radiotherapy (SABR) has emerged as a new treatment option for patients with oligometastatic disease. SABR delivers precise, high-dose, hypofractionated radiotherapy, and achieves excellent rates of local control...

Full description

Bibliographic Details
Main Authors: Palma David A, Haasbeek Cornelis J A, Rodrigues George B, Dahele Max, Lock Michael, Yaremko Brian, Olson Robert, Liu Mitchell, Panarotto Jason, Griffioen GwendolynHMJ, Gaede Stewart, Slotman Ben, Senan Suresh
Format: Article
Language:English
Published: BMC 2012-07-01
Series:BMC Cancer
Subjects:
Oligometastases
Stereotactic radiotherapy
Quality of life
Cancer
Survival
Online Access:http://www.biomedcentral.com/1471-2407/12/305

Internet

http://www.biomedcentral.com/1471-2407/12/305

Similar Items